Список литературы

Поставить закладку

Gournay V. The ductus arteriosus: Physiology, regulation, and functional and congenital anomalies // Arch. Cardiovasc. Dis. 2011. Vol. 104, № 11. P. 578–585.
Zonnenberg I., De Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review // Acta Paediatr. 2012. Vol. 101, № 3. P. 247–251.
Khanafer-Larocque I, Soraisham A, Stritzke A, Al Awad E, Thomas S, Murthy P, Kamaluddeen M, Scott JN M.K. Intraventricular Hemorrhage: Risk Factors and Association With Patent Ductus Arteriosus Treatment in Extremely Preterm Neonates // Front. Pediatr. 2019. Vol. 7. P. 408.
Semberova J. et al. Spontaneous Closure of Patent Ductus Arteriosus in Infants ≤1500 g // Artic. Pediatr. 2017. Vol. 140, № 2. P. 20164258.
Benitz W.E. Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants // FROM Am. Acad. Pediatr. Pediatr. 2016. Vol. 137, № 1.
Gentile R. et al. Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants // J. Pediatr. 1981. Vol. 98, № 3. P. 443–448.
Koch J. et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less // Pediatrics. 2006. Vol. 117, № 4. P. 1113–1121.
Sehgal A., McNamara P.J. International perspective on management of a patent ductus arteriosus: Lessons learned // Semin. Fetal Neonatal Med. Elsevier, 2018. Vol. 23, № 4. P. 278–284.
Lee J.A. et al. Perinatal risk factors of symptomatic preterm patent ductus arteriosus and secondary ligation // Pediatr. Neonatol. Elsevier Taiwan LLC, 2020. Vol. 61, № 4. P. 439– 446.
Park H.W. et al. Chorioamnionitis and Patent Ductus Arteriosus: A Systematic Review and Meta-Analysis // PLoS One. 2015. Vol. 10, № 9. P. 0138114.
Rakza T. et al. Early Hemodynamic Consequences of Patent Ductus Arteriosus in Preterm Infants with Intrauterine Growth Restriction // J. Pediatr. 2007. Vol. 151, № 6. P. 624–628.
Gonzalez A. et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less // J. Pediatr. 1996. Vol. 128, № 4. P. 470– 478.
Pourarian S. et al. Prevalence and risk factors associated with the patency of ductus arteriosus in premature neonates: a prospective observational study from Iran // J. Matern. Neonatal Med. 2017. Vol. 30, № 12. P. 1460–1464.
Simon S.R. et al. E-Mail Systematic Review and Meta-Analysis Platelet Counts and Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis // Neonatology. 2015. Vol. 108, № 2. P. 143–151.
In Sung S. et al. Natural evolution of ductus arteriosus with noninterventional conservative management in extremely preterm infants born at 23-28 weeks of gestation // PLoS One. 2019. Vol. 14, № 2. P. 0212256.
Lee J.A. et al. Current Status of Therapeutic Strategies for Patent Ductus Arteriosus in Very- Low-Birth-Weight Infants in Korea // J Korean Med Sci. 2015. Vol. 30, № suppl1. P. 59– 66.
Chiruvolu A., Punjwani P., Ramaciotti C. Clinical and echocardiographic diagnosis of patent ductus arteriosus in premature neonates // Early Hum. Dev. Elsevier Ltd, 2009. Vol. 85, № 3. P. 147–149.
Noori S. et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants // Pediatrics. 2009. Vol. 123, № 1. P. 138–144.
Clyman R.I., Couto J., Murphy G.M. Patent Ductus Arteriosus: Are Current Neonatal Treatment Options Better or Worse Than No Treatment at All? // Semin. Perinatol. Elsevier Inc., 2012. Vol. 36, № 2. P. 123–129.
Nemerofsky S.L. et al. The ductus arteriosus rarely requires treatment in infants > 1000 grams // Am. J. Perinatol. 2008. Vol. 25, № 10. P. 661–666.
Costa S. et al. Efficacy of a single dose of antenatal corticosteroids on morbidity and mortality of preterm infants // Eur. J. Obstet. Gynecol. Reprod. Biol. 2007. Vol. 131, № 2. P. 154–157.
Mcnamara P.J., Sehgal A.T. rational management of the patent ductus arteriosus: the need for disease staging. Disease Staging // Arch Dis Child Fetal Neonatal. 2007. Vol. 92. P. 424–427.
Van Laere D. et al. Application of Neonatologist Performed Echocardiography in the assessment of a patent ductus arteriosus // Pediatr Res. 2018. Vol. 84, № suppl 1. P. 46–56.
Singh Y., Katheria A., Tissot C. Functional Echocardiography in the Neonatal Intensive Care Unit // Indian Pediatr. 2018. Vol. 55, № 5. P. 417–424.
Urquhart DS N.R. How good is clinical examination at detecting a significant patent ductus arteriosus in the preterm neonate? // Arch Dis Child. 2003. Vol. 88, № 1. P. 85–86.
Erdeve Ö. et al. SIMPLE: A Novel Scoring System for Predicting Hemodynamically Significant Patent Ductus Arteriosus Without Echocardiographic Evaluation in Extremely Low Birth Weight Infants // Front. Pediatr. | www.frontiersin.org. 2021. Vol. 1. P. 649515.
Polglase G.R. et al. Circulatory insufficiency and Hypotension Related to the Ductus Arteriosus in Neonates // Front Pediatr. 2018. Vol. 6. P. 62.
Havranek T. et al. Feeding preterm neonates with patent ductus arteriosus (PDA): Intestinal blood flow characteristics and clinical outcomes // J. Matern. Neonatal Med. Informa Healthcare, 2015. Vol. 28, № 5. P. 526–530.
Lemmers P.M.A. et al. Patent Ductus Arteriosus and Brain Volume // Pediatrics. 2016. Vol. 137, № 4. P. 20153090.
Gillam-Krakauer M., Reese J. Diagnosis and management of patent ductus arteriosus // Neoreviews. 2018. Vol. 19, № 7. P. e394–e402.
Гнусаев С.Ф., Федерякина О.Б. ОТКРЫТЫЙ АРТЕРИАЛЬНЫЙ ПРОТОК У НЕДОНОШЕННЫХ НОВОРОЖДЕННЫХ: СОВРЕМЕННОЕ ПРЕДСТАВЛЕНИЕ О ДАВНЕЙ ПРОБЛЕМЕ // Астраханский медицинский жур нал. 2019. № 4822. P. 6–17.
Joshi R. et al. Anesthesia protocols for “bedside” preterm patent ductus arteriosus ligation: A single-institutional experience // Ann. Pediatr. Cardiol. 2021. Vol. 14, № 3. P. 343–349.
Bagnoli F. et al. Treatment of patent ductus arteriosus (PDA) using ibuprofen: Renal side- effects in VLBW and ELBW newborns // J. Matern. Neonatal Med. 2013. Vol. 26, № 4. P. 423–429.
Pacifici G.M. Differential renal adverse effects of ibuprofen and indomethacin in preterm infants: a review // Clin. Pharmacol. Adv. Appl. 2014. Vol. 31, № 6. P. 111–116.
Ndour D. et al. Adverse events related to ibuprofen treatment for patent ductus arteriosus in premature neonates // Arch. Pediatr. French Society of Pediatrics, 2020. Vol. 27, № 8. P. 452–455.
García-Robles A, Gimeno Navarro A, Serrano Martín MDM, Párraga Quiles MJ, Parra Llorca A, Poveda-Andrés JL, Vento Torres M A.C.M. Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol // Front. Pediatr. 2020. Vol. 1, № 8. P. 372.
Clyman R.I. et al. PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age // J. Pediatr. 2019. Vol. 205. P. 41–48.e6.
Kushnir A., Pinheiro J.M.B. Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts // BMC Clin. Pharmacol. 2011. Vol. 11.
Seo E.S. et al. Changes in serum creatinine levels and natural evolution of acute kidney injury with conservative management of hemodynamically significant patent ductus arteriosus in extremely preterm infants at 23–26 weeks of gestation // J. Clin. Med. 2020. Vol. 9, № 3. P. 17–21.
Park J.S. et al. Risk factors and effects of severe late-onset hyponatremia on long-term growth of prematurely born infants // Pediatr. Gastroenterol. Hepatol. Nutr. 2020. Vol. 23, № 5. P. 472–483.
Conrad C., Newberry D. Understanding the Pathophysiology, Implications, and Treatment Options of Patent Ductus Arteriosus in the Neonatal Population // Adv. Neonatal Care. Lippincott Williams and Wilkins, 2019. Vol. 19, № 3. P. 179–187.
Bardanzellu F. et al. Review Article Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe? // Biomed Res Int. 2017. P. 1438038.
Singh Y. et al. International evidence-based guidelines on Point of Care Ultrasound (POCUS) for critically ill neonates and children issued by the POCUS Working Group of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC) // Crit Care. 2020. Vol. 24, № 1. P. 65.
Job S. et al. Echocardiography-Guided Management of Preterms With Patent Ductus Arteriosus Influences the Outcome: A Cohort Study // Front Pediatr. 2020. Vol. 21, № 8. P. 582735.
Gillam-Krakauer M., Reese J. Diagnosis and management of patent ductus arteriosus // Neoreviews. American Academy of Pediatrics, 2018. Vol. 19, № 7. P. e394–e402.
Bravo M.C. et al. Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: A pilot study // J. Matern. Neonatal Med. Informa Healthcare, 2014. Vol. 27, № 9. P. 904–909.
Ting J.Y. et al. Predictors of respiratory instability in neonates undergoing patient ductus arteriosus ligation after the introduction of targeted milrinone treatment // J. Thorac. Cardiovasc. Surg. Elsevier Inc., 2016. Vol. 152, № 2. P. 498–504.
El-Khuffash A., McNamara P.J. Hemodynamic Assessment and Monitoring of Premature Infants // Clin. Perinatol. 2017. Vol. 44, № 2. P. 377–393.
EL-Khuffash A. et al. A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT) // J. Pediatr. 2021. Vol. 229. P. 127–133.
Smith A., El-Khuffash A. Patent ductus arteriosus clinical trials: Lessons learned and future directions // Children. 2021. Vol. 8, № 1. P. 47.
Elsayed Y.N., Fraser D. Patent ductus arteriosus in preterm infants, part 1: Understanding the pathophysiologic link between the patent ductus arteriosus and clinical complications // Neonatal Netw. Springer Publishing Company, 2017. Vol. 36, № 5. P. 265–272.
Н. В. Харламова, Е. М. Спивак, Ю. А. Фисюк, А. М. Климачев И.Г.П. ОТКРЫТЫЙ АРТЕРИАЛЬНЫЙ ПРОТОК У ГЛУБОКОНЕДОНОШЕННЫХ ДЕТЕЙ. Ярославль: Филигрань, 2021., 2021.
Jaleel M.A., Rosenfeld C.R. Patent ductus arteriosus and intraventricular hemorrhage: A complex association // J. Pediatr. 2013. Vol. 163, № 1. P. 8–10.
Kessler U, Schulte F, Cholewa D, Nelle M, Schaefer SC, Klimek PM B.S. Outcome in neonates with necrotizing enterocolitis and patent ductus arteriosus. // World J Pediatr. 2016. Vol. 12, № 1. P. 55–59.
Serafini G. et al. Preoperative evaluation in infants and children: Recommendations of the Italian Society of Pediatric and Neonatal Anesthesia and Intensive Care (SARNePI) // Minerva Anestesiol. 2014. Vol. 80, № 4. P. 461–469.
Bouissou A. et al. Hypotension in Preterm Infants with Significant Patent Ductus Arteriosus: Effects of Dopamine // J. Pediatr. 2008. Vol. 153, № 6. P. 790–794.
Nagata H. et al. Left ventricular efficiency after ligation of patent ductus arteriosus for premature infants // J. Thorac. Cardiovasc. Surg. Elsevier Inc., 2013. Vol. 146, № 6. P. 1353–1358.
Shah S., Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants // Cochrane Database Syst. Rev. 2018. Vol. 9, № 9. P. CD003481.
Ohlsson A S.S. Cochrane Database of Systematic Reviews Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants (Review) // Cochrane Database. 2018. Vol. 9, № 9. P. 003481.
Hamrick S.E.G., Hansmann G. Patent ductus arteriosus of the preterm infant // Pediatrics. 2010. Vol. 125, № 5. P. 1020–1030.
Marconi E. et al. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies // Pharmacol. Res. Elsevier, 2019. Vol. 148, № August. P. 104418.
Kluckow M., Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage // J. Pediatr. 2000. Vol. 137, № 1. P. 68–72.
Schena F. et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia // J. Pediatr. Elsevier Inc, 2015. Vol. 166, № 6. P. 1488– 1492.
Kaempf J.W. et al. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants // J. Perinatol. 2012. Vol. 32, № 5. P. 344– 348.
Terrin G. et al. Morbidity associated with patent ductus arteriosus in preterm newborns: a retrospective case-control study // Ital. J. Pediatr. Italian Journal of Pediatrics, 2021. Vol. 47, № 1. P. 4–11.
Jansen E.J.S. et al. Factors Associated With Benefit of Treatment of Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis // Front. Pediatr. 2021. Vol. 9, № February. P. 1–12.
Hirt D. et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study // Br J Clin Pharmacol. 2008. Vol. 65, № 5. P. 629–636.
Desfrere L. et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method // J. Clin. Pharm. Ther. 2005. Vol. 30. P. 121–132.
Mitra S. et al. Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants A Systematic Review and Meta-analysis // JAMA. 2018. Vol. 27, № 3. P. 1221–1238.
Slaughter J.L. et al. Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation // BMC Pediatr. 2019. Vol. 19, № 1. P. 333.
Gokmen T. et al. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus // J. Pediatr. Mosby Inc., 2011. Vol. 158, № 4. P. 549–554.e1.
Ferguson J.M. Pharmacotherapy for patent ductus arteriosus closure // Congenit. Heart Dis. Blackwell Publishing Ltd, 2019. Vol. 14, № 1. P. 52–56.
Dang D. et al. Comparison of Oral Paracetamol versus Ibuprofen in Premature Infants with Patent Ductus Arteriosus: A Randomized Controlled Trial // PLoS One. 2013. Vol. 8, № 11. P. 77888.
Manalastas M. et al. Acetaminophen therapy for persistent patent ductus arteriosus // Neoreviews. 2021. Vol. 22, № 5. P. e320–e331.
Ohlsson A S.P. Cochrane Database of Systematic Reviews Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants (Review) // Cochrane Database. 2018. Vol. 4, № 4. P. 010061.
El-Khuffash A. et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies // Pediatr Res. 2014. Vol. 76, № 3. P. 238–214.
Ohlsson A., Shah P.S. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants // Cochrane Database Syst. Rev. 2020. Vol. 2020, № 1.
Walls L., Baker C.F., Sarkar S. Acetaminophen-induced hepatic failure with encephalopathy in a newborn // J. Perinatol. 2007. Vol. 27, № 2. P. 133–135.
Mashally S. et al. Is late treatment with acetaminophen safe and effective in avoiding surgical ligation among extremely preterm neonates with persistent patent ductus arteriosus? // J. Perinatol. Springer US, 2021. Vol. 41, № 10. P. 2519–2525.
Noureldein M. et al. Paracetamol for patent ductus arteriosus in preterm infants: a UK national survey // J. Matern. Neonatal Med. 2020. Vol. 7058.
Bardanzellu F. et al. Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe? // Biomed Res. Int. 2017. Vol. 2017.
van den Anker J.N., Allegaert K. Acetaminophen in the Neonatal Intensive Care Unit: Shotgun Approach or Silver Bullet // J. Pediatr. Elsevier Inc., 2018. Vol. 198. P. 10–11.
Terrin G. et al. Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: A systematic review and meta-analysis // Arch. Dis. Child. Fetal Neonatal Ed. BMJ Publishing Group, 2016. Vol. 101, № 2. P. F127–F136.
Oncel M.Y. et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: A randomized controlled trial // J. Pediatr. 2014. Vol. 164, № 3. P. 510–514.
Graham G.G. et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings // Inflammopharmacology. 2013. Vol. 21, № 3. P. 201–232.
Dani C. et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial // Eur. J. Pediatr. European Journal of Pediatrics, 2021. Vol. 180, № 3. P. 807–816.
Jasani B., Weisz D.E., McNamara P.J. Evidence-based use of acetaminophen for hemodynamically significant ductus arteriosus in preterm infants // Semin. Perinatol. Elsevier, 2018. Vol. 42, № 4. P. 243–252.
Dani C. et al. Patent ductus arteriosus in preterm infants born at 23–24 weeks’ gestation: Should we pay more attention? // Early Hum. Dev. 2019. Vol. 135, № April. P. 16–22.
Benitz W.E. Treatment of persistent patent ductus arteriosus in preterm infants: Time to accept the null hypothesis // J. Perinatol. Nature Publishing Group, 2010. Vol. 30, № 4. P. 241–252.
Benitz W.E. Patent Ductus Arteriosus in Preterm Infants // Pediatrics. 2016. Vol. 137, № 1. P. 1–6.
Carmo K.B., Evans N., Paradisis M. Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography // J. Pediatr. Mosby Inc., 2009. Vol. 155, № 6. P. 812–822.
Evans N. Preterm patent ductus arteriosus: A continuing conundrum for the neonatologist? // Semin. Fetal Neonatal Med. Elsevier Ltd, 2015. Vol. 20, № 4. P. 272–277.
Hamrick S.E.G. et al. Patent ductus arteriosus of the preterm infant // Pediatrics. 2020. Vol. 146, № 5.
Abushaban L. et al. Normal reference ranges for left ventricular dimensions in preterm infants // Ann. Pediatr. Cardiol. 2014. Vol. 7, № 3. P. 180–186.
Abu-Shaweesh J.M., Almidani E. PDA: Does it matter? // Int. J. Pediatr. Adolesc. Med. Elsevier Ltd, 2020. Vol. 7, № 1. P. 9–12.
Su B.H. et al. Therapeutic strategy of patent ductus arteriosus in extremely preterm infants // Pediatr. Neonatol. Elsevier Taiwan LLC, 2020. Vol. 61, № 2. P. 133–141.
Su B.H. et al. Circulatory Management Focusing on Preventing Intraventricular Hemorrhage and Pulmonary Hemorrhage in Preterm Infants // Pediatrics and Neonatology. Elsevier (Singapore) Pte Ltd, 2016. Vol. 57, № 6. P. 453–462.
Ibrahim T. et al. Selective Treatment of PDA in High-Risk VLBW Infants With Birth Weight ≤800 g or <27 Weeks and Short-Term Outcome: A Cohort Study // Front. Pediatr. 2021. Vol. 8, № January. P. 1–10.
Mitra S. et al. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2020. Vol. 2020, № 12.
Isayama T. et al. Patent Ductus Arteriosus Management and Outcomes in Japan and Canada: Comparison of Proactive and Selective Approaches // Am. J. Perinatol. 2015. Vol. 32, № 11. P. 1087–1094.
Sankar M.N., Bhombal S., Benitz W.E. PDA: To treat or not to treat // Congenit. Heart Dis. Blackwell Publishing Ltd, 2019. Vol. 14, № 1. P. 46–51.
Rozé J.C. et al. Association between early screening for patent ductus arteriosus and in- hospital mortality among extremely preterm infants // JAMA - J. Am. Med. Assoc. 2015. Vol. 313, № 24. P. 2441–2448.
Sellmer A. et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3 // Arch. Dis. Child. Fetal Neonatal Ed. 2013. Vol. 98, № 6. P. 505–510.
Bell J.L. et al. Correction to: Baby-OSCAR: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies—a statistical analysis plan for short- term outcomes (Trials, (2021), 22, 1, (368), 10.1186/s13063-021-05324-3) // Trials. Trials, 2021. Vol. 22, № 1. P. 13063.
Cambonie G., Clyman R.I., Rozé J.C. Management of persistent ductus arteriosus in very premature neonates. Results of the French TRIOCAPI trial, perspectives for clinicians, and subsequent studies on this topic // Arch. Pediatr. 2021. Vol. 28, № 7. P. 501–503.
Hundscheid T. et al. Multi-centre, randomised non-inferiority trial of early treatment versus expectant management of patent ductus arteriosus in preterm infants (the BeNeDuctus trial): statistical analysis plan // Trials. Trials, 2021. Vol. 22, № 1. P. 1–12.
Berry M.J. et al. Outcomes of 23- and 24-weeks gestation infants in Wellington, New Zealand: A single centre experience // Sci. Rep. 2017. Vol. 7, № 1. P. 3–10.
Emre Canpolat F. et al. Conservative Non-intervention Approach for Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants // Front Pediatr. 2020. Vol. 23, № 8. P. 605134.
Dani C. et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: A randomized controlled study // Clin. Pharmacol. Ther. Nature Publishing Group, 2012. Vol. 91, № 4. P. 590–596.
Meißner U. et al. Improved closure of patent ductus arteriosus with high doses of ibuprofen // Pediatr. Cardiol. 2012. Vol. 33, № 4. P. 586–590.
Sallmon H., Koehne P., Hansmann G. Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus // Clin. Perinatol. 2016. Vol. 43, № 1. P. 113–129.
Shin J. et al. Conservative Treatment Without Any Intervention Compared With Other Therapeutic Strategies for Symptomatic Patent Ductus Arteriosus in Extremely Preterm Infants: A Nationwide Cohort Study in Korea // Front. Pediatr. 2021. Vol. 9, № October. P. 1–8.
Willis K.A., Weems M.F. Hemodynamically significant patent ductus arteriosus and the development of bronchopulmonary dysplasia // Congenit. Heart Dis. 2019. Vol. 14, № 1. P. 27–32.
de Boode W.P. et al. Role of neonatologist-performed echocardiography in the assessment and management of patent ductus arteriosus physiology in the newborn // Seminars in Fetal and Neonatal Medicine. W.B. Saunders Ltd, 2018. Vol. 23, № 4. P. 292–297.
Richards J. et al. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants // Pediatrics. 2009. Vol. 124, № 2. P. 287–293.
Nadir E. et al. Paracetamol treatment of patent ductus arteriosus in preterm infants // J. Perinatol. 2014. Vol. 34, № 10. P. 748–749.
Allegaert K. et al. Paracetamol to induce ductus arteriosus closure: Is it valid? // Archives of Disease in Childhood. 2013. Vol. 98, № 6. P. 462–466.
Constance J.E. et al. Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin // J. Perinatol. Nature Publishing Group, 2017. Vol. 37, № 10. P. 1093–1102.
Weisz D.E., Giesinger R.E. Surgical management of a patent ductus arteriosus: Is this still an option? // Seminars in Fetal and Neonatal Medicine. W.B. Saunders Ltd, 2018. Vol. 23, № 4. P. 255–266.
Malviya M., Ohlsson A., Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2008. № 1. P. 003951.
Weisz D.E. et al. PDA liǵation and health outcomes: A meta-analysis // Pediatrics. American Academy of Pediatrics, 2014. Vol. 133, № 4.
Ngo S., Profit J., Gould J.B. Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants // Pediatrics. 2017. Vol. 139, № 4. P. 20162390.
Park J. et al. Patent ductus arteriosus treatment trends and associated morbidities in neonates // Sci. Reports |. 2021. Vol. 11, № 1. P. 10689.
Mirea L. et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: Adjustment for treatment selection bias // J. Pediatr. Mosby Inc., 2012. Vol. 161, № 4.
Разумовский А.Ю., Алхасов А.Б., Митупов З.Б., Феоктистова Е.В., Ситникова М.И., Коллеров М.Ю. Н.Ю.В. ХИРУРГИЧЕСКАЯ КОРРЕКЦИЯ ОТКРЫТОГО АРТЕРИАЛЬНОГО ПРОТОКА У ДЕТЕЙ // Российский вестник десткой хирургии, анестезиологии и реаниматологии. 2017. P. 25–33.
Марасина А. В., Горелик Ю. В., Шихранов А. А., Цытко А. Л., Анцыгин Н. В., Мостовой А. В. М.Р.Р. Хирургическое лечение открытого артериального протока у недоношенных детей с низкой массой тела // Научно-практический журнал Детские болезни сердца и сосудов. 2012. Vol. 1.
Reese J. et al. Management of Patent Ductus Arteriosus in Premature Infants in 2020 // Front. Pediatr. | www.frontiersin.org. 2021. Vol. 8. P. 590578.
Scerbo D. et al. Percutaneous Closure of the Patent Ductus Arteriosus in Very-Low-Weight Infants Practice Gaps // Neoreviews. 2020. Vol. 21, № 7. P. 469–478.
Agrawal H. et al. New Patent Ductus Arteriosus Closure Devices and Techniques // Interventional Cardiology Clinics. Elsevier Inc., 2019. Vol. 8, № 1. P. 23–32.
Janvier A. et al. Anesthetic technique and postoperative outcome in preterm infants undergoing PDA closure // J. Perinatol. 2010. Vol. 30, № 10. P. 677–682.
Wyllie J. Treatment of patent ductus arteriosus // Semin. Neonatol. W.B. Saunders Ltd, 2003. Vol. 8, № 6. P. 425–432.
Jain A. et al. Use of targeted neonatal echocardiography to prevent postoperative cardiorespiratory instability after patent ductus arteriosus ligation // J. Pediatr. Mosby Inc., 2012. Vol. 160, № 4.
Halliday M. et al. Milrinone use for hemodynamic instability in patent ductus arteriosus ligation // J. Matern. Neonatal Med. Taylor and Francis Ltd, 2017. Vol. 30, № 5. P. 529– 533.
Ulrich T.J.B. et al. Post-ligation cardiac syndrome is associated with increased morbidity in preterm infants // J. Perinatol. 2018. Vol. 38. P. 537–542.
McNamara P.J. et al. Patent ductus arteriosus ligation is associated with impaired left ventricular systolic performance in premature infants weighing less than 1000 g // J. Thorac. Cardiovasc. Surg. 2010. Vol. 140, № 1. P. 150–157.
Serrano R.M. et al. Comparison of “post-patent ductus arteriosus ligation syndrome” in premature infants after surgical ligation vs. percutaneous closure // J. Perinatol. Springer Nature, 2020. Vol. 40, № 2. P. 324–329.
Sarkar S., Dechert R., Donn S.M. Is refractory hypotension in preterm infants a manifestation of early ductal shunting? // J. Perinatol. 2007. Vol. 27, № 6. P. 353–358.
Giesinger R.E., McNamara P.J. Hemodynamic instability in the critically ill neonate: An approach to cardiovascular support based on disease pathophysiology // Seminars in Perinatology. W.B. Saunders, 2016. Vol. 40, № 3. P. 174–188.
Bell E., Acarregui M. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants // Cochrane Database Syst. Rev. John Wiley & Sons, Ltd, 2001. № 2. P. 000503.
Brion L.P., Campbell D. Furosemide for prevention of morbidity in indomethacin-treated infants with patent ductus arteriosus // Cochrane Database Syst. Rev. Wiley, 2001. № 3. P. 001148.
Cotton R., Suarez S., Reese J. Unexpected extra-renal effects of loop diuretics in the preterm neonate // Acta Paediatr. Int. J. Paediatr. 2012. Vol. 101, № 8. P. 835–845.
Noori S. et al. Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants // J. Perinatol. 2009. Vol. 29, № 8. P. 553–557.
Vanhaesebrouck S. et al. Conservative treatment for patent ductus arteriosus in the preterm // Arch Dis Child Fetal Neonatal Ed. 2007. Vol. 92, № 4. P. 244–247.
Letshwiti J.B. et al. A conservative treatment of patent ductus arteriosus in very low birth weight infants // Early Hum. Dev. Elsevier Ireland Ltd, 2017. Vol. 104. P. 45–49.
Martini S. et al. To Feed or Not to Feed: A Critical Overview of Enteral Feeding Management and Gastrointestinal Complications in Preterm Neonates with a Patent Ductus Arteriosus // Nutrients. 2019. Vol. 12, № 1. P. 83.
Benitz W.E., Bhombal S. The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infants // Seminars in Fetal and Neonatal Medicine. W.B. Saunders Ltd, 2017. Vol. 22, № 5. P. 302–307.
Ohlsson A S.S. Cochrane Database of Systematic Reviews Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants (Review) // Cochrane Database Syst. Rev. 2020. Vol. 2. P. 003481.
Liebowitz M., Clyman R.I. Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes // J. Pediatr. Mosby Inc., 2017. Vol. 187. P. 119–126.e1.
Van Overmeire B A.K.C.A.D.C.D.W.J.A.W.J.H.I.L.J. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. // Lancet. 2004. Vol. 364, № 9449. P. 1945–1949.
Narayan S.A. et al. Long-term follow-up is not indicated after routine interventional closure of persistent arterial ducts // Catheter. Cardiovasc. Interv. John Wiley and Sons Inc., 2015. Vol. 86, № 1. P. 100–104.
Babla K., Shetty S., Kulkarni A. A clinical and echocardiographic approach to evaluation of patent ductus arteriosus in preterm infants // Paediatr. Child Heal. (United Kingdom). Elsevier Ltd, 2020. Vol. 30, № 4. P. 129–134.
de Freitas Martins F. et al. Relationship of Patent Ductus Arteriosus Size to Echocardiographic Markers of Shunt Volume // J. Pediatr. Elsevier Inc., 2018. Vol. 202. P. 50–55.e3.
El-Saiedi S. et al. Development of tissue Doppler-derived predictors of hemodynamically significant patent ductus arteriosus and the ability to incorporate it in targeted neonatal echocardiography protocol // J. Saudi Hear. Assoc. King Saud University, 2019. Vol. 31, № 2. P. 69–74.
Siassi, Bijan; Noori, Shahab; Wong, Pierre; Acherman R. Practical Neonatal Echocardiography. McGraw-Hill Education. 2019. 2020. Vol. 8, № November. 1-11 p.
Siassi, Bijan; Noori, Shahab; Wong, Pierre; Acherman R.M.-H.E. Practical Neonatal Echocardiography. 1th ed. Mc Graw Hill Education, 2019.
Rios D.R. et al. Early Role of the Atrial-Level Communication in Premature Infants with Patent Ductus Arteriosus // J. Am. Soc. Echocardiogr. American Society of Echocardiography, 2021. Vol. 34, № 4. P. 423–432.e1.
Naulaers G. et al. Echocardiographic Diagnosis and Hemodynamic Evaluation of Patent Ductus Arteriosus in Extremely Low Gestational Age Newborn (ELGAN) Infants // Front. Pediatr. | www.frontiersin.org. 2020. Vol. 8. P. 573627.
Ficial B. et al. Survey of PDA management in very low birth weight infants across Italy // Ital. J. Pediatr. Italian Journal of Pediatrics, 2020. Vol. 46, № 1. P. 1–8.
Guthrie J.D. A noel echocardiographic marker (PDAM) incorporating the diameter of the patent foramen ovale to assess hemodynamically significant patent ductus arteriosus // J. Diagnostic Med. Sonogr. 2015. Vol. 31, № 1. P. 30–37.
Jain A., Shah P.S. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates // JAMA Pediatr. 2015. Vol. 169, № 9. P. 863–872.
Guo X. et al. Identification of the hemodynamic significant patent ductus arteriosus in preterm infants // Hong Kong J. Pediatr. Res. 2021. Vol. 4, № 1. P. 17–20.
Choi E.K., Park K.H., Choi B.M. Size of Patent Ductus Arteriosus and Echocardiographic Markers of Shunt Volume in Preterm Infants Based on Postnatal Age // Front. Pediatr. 2021. Vol. 9, № April. P. 1–7.
Lopez L. et al. Recommendations for Quantification Methods During the Performance of a Pediatric Echocardiogram: A Report From the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council // J. Am. Soc. Echocardiogr. Elsevier Inc, 2010. Vol. 23, № 5. P. 465–495.
de Boode W.P. et al. The role of Neonatologist Performed Echocardiography in the assessment and management of neonatal shock // Pediatr. Res. 2018. Vol. 84, № 1. P. 57– 67.
Ficial B. et al. Validation study of the accuracy of echocardiographic measurements of systemic blood flow volume in newborn infants // J. Am. Soc. Echocardiogr. Elsevier Inc, 2013. Vol. 26, № 12. P. 1365–1371.
Bischoff A.R. et al. Assessment of superior vena cava flow and cardiac output in different patterns of patent ductus arteriosus shunt // Echocardiography. 2021. № July. P. 1–10.
Smith A., El-Khuffash A.F. Defining “haemodynamic significance” of the patent ductus arteriosus: do we have all the answers? // Neonatology. 2020. Vol. 117, № 2. P. 225–232.
Polat T.B., Celik I.H., Erdeve O. Early predictive echocardiographic features of hemodynamically significant patent ductus arteriosus in preterm VLBW infants // Pediatr. Int. 2016. Vol. 58, № 7. P. 589–594.
Jantzen D.W. et al. Is combined atrial volumetrics by two-dimensional echocardiography a suitable measure for quantitative assessment of the hemodynamic significance of patent ductus arteriosus in neonates and infants? // Echocardiography. 2010. Vol. 27, № 6. P. 696– 701.